Compagnie Lombard Odier SCmA Acquires 11,992 Shares of Johnson & Johnson $JNJ

Key Points

• Compagnie Lombard Odier SCmA increased its holdings in Johnson & Johnson by 3.8%, acquiring an additional 11,992 shares to reach a total of 323,578 shares valued at approximately $49.4 million.
• Johnson & Johnson reported a quarterly EPS of $2.77, exceeding analysts' expectations of $2.68, along with a revenue of $23.74 billion for the quarter.
• The company announced a quarterly dividend of $1.30 per share, reflecting an annualized dividend of $5.20 with a yield of 2.9%.

Compagnie Lombard Odier SCmA grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 323,578 shares of the company's stock after purchasing an additional 11,992 shares during the period. Compagnie Lombard Odier SCmA's holdings in Johnson & Johnson were worth $49,427,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of JNJ. Lantz Financial LLC raised its stake in Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after acquiring an additional 377 shares in the last quarter. Apexium Financial LP grew its holdings in shares of Johnson & Johnson by 10.7% during the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company's stock valued at $3,978,000 after purchasing an additional 2,310 shares during the last quarter. Joel Isaacson & Co. LLC lifted its stake in Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after purchasing an additional 2,526 shares during the last quarter. Avanza Fonder AB boosted its position in Johnson & Johnson by 2.9% in the second quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock valued at $35,842,000 after buying an additional 6,566 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. grew its stake in shares of Johnson & Johnson by 7.0% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock worth $12,164,000 after buying an additional 4,816 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $176.35 on Wednesday. The stock's 50-day simple moving average is $173.56 and its 200 day simple moving average is $161.79. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a market capitalization of $424.71 billion, a price-to-earnings ratio of 18.86, a price-to-earnings-growth ratio of 2.22 and a beta of 0.40. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of research reports. Citigroup increased their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research note on Thursday, August 21st. Bank of America lifted their price target on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday, July 17th. Morgan Stanley boosted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Guggenheim upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price objective for the company from $167.00 to $206.00 in a report on Tuesday. Finally, Royal Bank Of Canada boosted their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $181.40.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.